JP2023510351A5 - - Google Patents
Info
- Publication number
- JP2023510351A5 JP2023510351A5 JP2022542337A JP2022542337A JP2023510351A5 JP 2023510351 A5 JP2023510351 A5 JP 2023510351A5 JP 2022542337 A JP2022542337 A JP 2022542337A JP 2022542337 A JP2022542337 A JP 2022542337A JP 2023510351 A5 JP2023510351 A5 JP 2023510351A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- complex according
- complex
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959804P | 2020-01-10 | 2020-01-10 | |
| US62/959,804 | 2020-01-10 | ||
| US202062965754P | 2020-01-24 | 2020-01-24 | |
| US62/965,754 | 2020-01-24 | ||
| US202062968411P | 2020-01-31 | 2020-01-31 | |
| US62/968,411 | 2020-01-31 | ||
| US202062980925P | 2020-02-24 | 2020-02-24 | |
| US62/980,925 | 2020-02-24 | ||
| US202063055521P | 2020-07-23 | 2020-07-23 | |
| US63/055,521 | 2020-07-23 | ||
| US202063061836P | 2020-08-06 | 2020-08-06 | |
| US63/061,836 | 2020-08-06 | ||
| US202063069067P | 2020-08-23 | 2020-08-23 | |
| US63/069,067 | 2020-08-23 | ||
| US202063132929P | 2020-12-31 | 2020-12-31 | |
| US63/132,929 | 2020-12-31 | ||
| PCT/US2021/012764 WO2021142313A1 (en) | 2020-01-10 | 2021-01-08 | Muscle-targeting complexes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510351A JP2023510351A (ja) | 2023-03-13 |
| JP2023510351A5 true JP2023510351A5 (cg-RX-API-DMAC7.html) | 2024-01-17 |
Family
ID=76788871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542337A Pending JP2023510351A (ja) | 2020-01-10 | 2021-01-08 | 筋標的化複合体およびそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230226212A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087876A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023510351A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427448A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163608A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142313A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525611A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2022309238A1 (en) * | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US20240390508A1 (en) * | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US20250177433A1 (en) * | 2021-09-01 | 2025-06-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
| WO2023034870A2 (en) * | 2021-09-01 | 2023-03-09 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dmpk expression |
| US12071621B2 (en) * | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2025522433A (ja) | 2022-06-15 | 2025-07-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | スーパーオキシドジスムターゼ１（ＳＯＤ１）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用の方法 |
| WO2025072886A1 (en) * | 2023-09-28 | 2025-04-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| US20250121085A1 (en) * | 2023-10-02 | 2025-04-17 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping |
| WO2025085810A2 (en) * | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| CN118531138B (zh) * | 2024-06-18 | 2025-04-01 | 湖北省农业科学院畜牧兽医研究所 | 猪肉品质和胴体关联的snp及应用 |
| WO2025262186A2 (en) * | 2024-06-20 | 2025-12-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Therapeutic oligonucleotides for treating diseases being associated with or caused by a missense, nonsense or in-frame indel mutation |
| CN118516348B (zh) * | 2024-07-23 | 2025-01-17 | 深川生物科技(山东)股份公司 | 单链核酸或双链核酸及在制备治疗杜氏肌营养不良的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| MX2019008199A (es) * | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| JP7303110B2 (ja) * | 2017-01-18 | 2023-07-04 | ビステラ， インコーポレイテッド | 抗体分子－薬物コンジュゲートおよびその使用 |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
-
2021
- 2021-01-08 CA CA3163608A patent/CA3163608A1/en active Pending
- 2021-01-08 JP JP2022542337A patent/JP2023510351A/ja active Pending
- 2021-01-08 US US17/791,667 patent/US20230226212A1/en active Pending
- 2021-01-08 WO PCT/US2021/012764 patent/WO2021142313A1/en not_active Ceased
- 2021-01-08 CN CN202180022140.7A patent/CN115427448A/zh active Pending
- 2021-01-08 EP EP21738007.0A patent/EP4087876A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510351A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512441A5 (cg-RX-API-DMAC7.html) | ||
| JP2023512442A5 (cg-RX-API-DMAC7.html) | ||
| JP2023509793A5 (cg-RX-API-DMAC7.html) | ||
| JP2024501872A5 (cg-RX-API-DMAC7.html) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| JP7829488B2 (ja) | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 | |
| JP2021533199A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535078A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533200A5 (cg-RX-API-DMAC7.html) | ||
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2021532832A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535444A5 (cg-RX-API-DMAC7.html) | ||
| JP2023510350A5 (cg-RX-API-DMAC7.html) | ||
| JP2021533197A5 (cg-RX-API-DMAC7.html) | ||
| JP2023535074A5 (cg-RX-API-DMAC7.html) | ||
| IL294478A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| IL294480A (en) | Muscle-oriented complexes and their uses for the treatment of atrophy of the muscles of the face, shoulder blades, and arms | |
| JP2021533198A5 (cg-RX-API-DMAC7.html) | ||
| CA3226301A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| CA3226307A1 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| KR20230042713A (ko) | 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기 위한 그의 용도 | |
| JP2022513482A5 (cg-RX-API-DMAC7.html) | ||
| IL319265A (en) | Anti-transferrin receptor antibodies and their uses |